Navigation Links
Bacterin International to Present at Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
Date:8/23/2011

BELGRADE, Mont., Aug. 23, 2011 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE Amex: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, has been invited to present at the Rodman & Renshaw Annual Global Investment Conference. The conference will be held at The Waldorf Astoria Hotel in New York City on September 11-13, 2011.

Bacterin's chairman and CEO, Guy Cook, and CFO, John Gandolfo, are scheduled to present on Monday, September 12, 2011 at 1:35 p.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company's business plan and objectives for the remainder of 2011.

The presentation will be available via webcast at www.wsw.com/webcast/rrshq20/bone. A replay link will also be available for 90 days following the live presentation on the company's website at www.bacterin.com.

Bacterin recently reported record revenue for the second quarter 2011 of $7.5 million, up 25% sequentially and 135% year-over-year. The company also reported its first positive EBITDA quarter of $33,000.

For more information about the conference or to schedule a one-on-one meeting with Bacterin management, contact your Rodman & Renshaw representative or the conference desk at 212-920-3595.

About Bacterin International Holdings

Bacterin International Holdings, Inc. (NYSE Amex: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.

Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.

Investor Relations:
Liolios Group, Inc.
Scott Liolios or Ron Both
Tel 949-574-3860
info@liolios.com


'/>"/>
SOURCE Bacterin International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bacterin Second Quarter 2011 Revenues up 135% Over Prior Year, Driving First Positive EBITDA Quarter
2. Bacterin Secures $15 Million Credit Facility with MidCap Financial and Silicon Valley Bank
3. Bacterin Sets Second Quarter 2011 Conference Call for Thursday, August 11, 2011 at 4:30 p.m. ET
4. Bacterin Joins Russell 3000, Russell Microcap, and Russell Global Indexes
5. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
6. Bacterin International Holdings, Inc. Reports First Quarter 2011 Financial Results
7. Bacterin International Holdings Launches Third Biologic Scaffold
8. Bacterin International Holdings, Inc. Schedules Conference Call to Present Fourth Quarter and Full Year 2010 Financial Results
9. Bacterin International Holdings, Inc. Receives Approval for Listing on NYSE Amex
10. Bacterin International Announces Major Orthopedic Hospital Group to Begin Use of OsteoSponge®SC
11. Bacterin International to Announce Launch of OsteoSponge®SC at American Academy of Orthopedic Surgeons 2011 Annual Meeting February 15-19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/11/2017)... , June 10, 2017  Eli Lilly and Company ... from three Phase 3 studies of galcanezumab, an investigational ... including late-breaking data on several key secondary endpoints for ... results from these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will ... annual scientific meeting in Boston . ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... June 28, 2017 , ... Park Systems , a leader in Atomic ... SEMICONWest attendees and Park customers on July 11, 2017 from 12-2pm at the ... Chairman & CEO of Park Systems, and Prof. Krishna Saraswat , Rickey/Nielsen Professor ...
(Date:6/28/2017)... ... June 28, 2017 , ... Doner Financial, ... regions access to insurance assistance and financial planning services, is announcing the commencement ... families in the region facing financial crisis. , Matthew 25: Ministries (M25M) is ...
(Date:6/27/2017)... ... 2017 , ... Excel Medical, the leader in Next-Generation Medical ... Executive Vice President, Sales and Marketing. Finnegan is a widely known industry leader ... leadership. He has received industry recognition for innovations and new approaches to sales ...
(Date:6/27/2017)... , ... June 27, 2017 , ... Harbour , ... token assets on the Ethereum blockchain, has released their technical specifications . , ... there has been little systematic approach for determining which offerings will garner the greatest ...
(Date:6/27/2017)... ... June 27, 2017 , ... ... Association’s SUNucate efforts, Louisiana became the sixth state to pass legislation which ... Governor John Bel Edwards’ signature, Louisiana joins the states of Alabama, Arizona, Florida, ...
Breaking Medicine News(10 mins):